Literature DB >> 24307577

Interleukin-10 promoter (-1082) polymorphism in association with repeated hospital-acquired infections in elderly patients.

Phuong-Nhi Bories1, Marie Laurent, Evelyne Liuu, Lydie Denjean, Theodora Popovici, Elena Paillaud.   

Abstract

BACKGROUND: Infections are frequent complications of hospitalization, particularly in the elderly. Pro- and anti-inflammatory cytokines are essential components of the host response to pathogens and polymorphisms in their genes may contribute to inter-individual variations of the inflammatory response. The aim of this study was to investigate whether cytokine polymorphisms, separately or in combination, could be determining factors in the development of repeated nosocomial infections in elderly hospitalized patients.
METHODS: Tumor necrosis factor-α (-308) and (-238), interleukin-6 (-174) and (-6331), interleukin-10 (-1082) and (-592) polymorphisms were genotyped by PCR and hybridization with fluorescent-labeled probes in 245 hospitalized elderly patients (mean age 85.2 years; SD 6) and compared with those in 145 healthy adults.
RESULTS: The distribution of genotypes did not differ between elderly patients and control subjects. The presence of the interleukin-10 A(592) or A(1082) allele was more frequent individually and after adjustment for multiple comparisons in patients who suffered from several infections (p = 0.012, odds ratio = 5.3; 95 % confidence interval = 1.2-23.1).
CONCLUSION: Our data support a determinant role for interleukin-10 (-1082) polymorphism in the development of nosocomial infections.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24307577     DOI: 10.1007/s40520-013-0177-8

Source DB:  PubMed          Journal:  Aging Clin Exp Res        ISSN: 1594-0667            Impact factor:   3.636


  1 in total

1.  Clinical relevance of single nucleotide polymorphisms within the 13 cytokine genes in North Indian trauma hemorrhagic shock patients.

Authors:  Dablu Lal Gupta; Predeep Kumar Nagar; Vineet Kumar Kamal; Sanjeev Bhoi; D N Rao
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2015-11-11       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.